Volume | 6,597 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioVie Inc | BIVI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.6463 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
121 | 6,597 | - | 0.641 - 10.2799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
07:46:36 | formt | 300 | $ 0.6463 | USD |
BioVie Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
25.92M | 39.87M | - | 0 | -50.26M | -1.26 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioVie News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.68 | 0.7202 | 0.641 | 0.6778556 | 1,347,709 | -0.0337 | -4.96% |
1 Month | 1.23 | 3.31 | 0.641 | 1.57 | 6,753,852 | -0.5837 | -47.46% |
3 Months | 1.29 | 3.31 | 0.641 | 1.54 | 2,549,956 | -0.6437 | -49.90% |
6 Months | 3.21 | 5.82 | 0.641 | 1.89 | 1,559,444 | -2.56 | -79.87% |
1 Year | 10.00 | 10.2799 | 0.641 | 2.41 | 895,858 | -9.35 | -93.54% |
3 Years | 20.11 | 23.86 | 0.641 | 4.08 | 477,162 | -19.46 | -96.79% |
5 Years | 10.50 | 46.0977 | 0.641 | 4.57 | 420,016 | -9.85 | -93.84% |
BioVie Description
BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |